Literature DB >> 24629399

Regulation of expression of relaxin-3 and its receptor RXFP3 in the brain of diet-induced obese rats.

Christophe Lenglos1, Arojit Mitra1, Geneviève Guèvremont1, Elena Timofeeva2.   

Abstract

An animal model closely related to human obesity is diet-induced obesity in Sprague-Dawley rats. These rats placed on a high-energy (HE) diet show wide distribution in body weight gain with a subset of animals developing diet-induced obesity (DIO) and the remaining animals showing a diet-resistant (DR) phenotype. Once obesity is established, DIO rats strongly defend their increased body weight against caloric restriction. There is evidence that neuropeptide relaxin-3 is involved in food intake regulation, but the levels of expression of relaxin-3 and its receptor have not been yet demonstrated in the DIO model. The present study investigated the brain expression of relaxin-3 and its cognate receptor RXFP3 in DIO and DR rats maintained on an HE diet since weaning. Expression of relaxin-3 and RXFP3 mRNAs was assessed by in situ hybridization in ad libitum, food-deprived (12 h) and refed (1 h) feeding states. The levels of expression of relaxin-3 in the medial portion of the nucleus incertus (NI) were higher in the DIO rats compared to the DR rats in the ad libitum-fed state. Food deprivation increased the levels of expression of relaxin-3 in the medial NI in DR but not DIO rats. The stronger expression of relaxin-3 in the ad libitum-fed state in the DIO rats was accompanied by low expression of the RXFP3 receptor in the paraventricular hypothalamic nucleus (PVN), supraoptic nucleus, central amygdala (CeA), NI, and nucleus of the solitary tract (NTS). Refeeding increased expression of RXFP3 in the paraventricular thalamic nucleus, parvocellular PVN, CeA, NI, and NTS in the DIO rats. These results provide evidence that DIO rats show a constitutive increase in relaxin-3 expression in the medial NI and that refeeding after food deprivation may enhance the orexigenic effects of relaxin-3 in DIO rats by rapid upregulation of the expression of RXFP3 in the specific brain regions involved in food intake regulation.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diet; Obesity; RXFP3; Relaxin-3

Mesh:

Substances:

Year:  2014        PMID: 24629399     DOI: 10.1016/j.npep.2014.02.002

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  9 in total

1.  Relaxin-3/RXFP3 signalling in mouse hypothalamus: no effect of RXFP3 activation on corticosterone, despite reduced presynaptic excitatory input onto paraventricular CRH neurons in vitro.

Authors:  C Zhang; D V Baimoukhametova; C M Smith; J S Bains; Andrew L Gundlach
Journal:  Psychopharmacology (Berl)       Date:  2017-03-17       Impact factor: 4.530

Review 2.  Sex-specific effects of relaxin-3 on food intake and body weight gain.

Authors:  Juliane Calvez; Camila de Ávila; Elena Timofeeva
Journal:  Br J Pharmacol       Date:  2016-07-13       Impact factor: 8.739

3.  Inhibition of oxytocin and vasopressin neuron activity in rat hypothalamic paraventricular nucleus by relaxin-3-RXFP3 signalling.

Authors:  Alan Kania; Anna Gugula; Agnieszka Grabowiecka; Camila de Ávila; Tomasz Blasiak; Zenon Rajfur; Marian H Lewandowski; Grzegorz Hess; Elena Timofeeva; Andrew L Gundlach; Anna Blasiak
Journal:  J Physiol       Date:  2017-02-27       Impact factor: 5.182

Review 4.  The Relaxin-3 Receptor, RXFP3, Is a Modulator of Aging-Related Disease.

Authors:  Hanne Leysen; Deborah Walter; Lore Clauwaert; Lieselot Hellemans; Jaana van Gastel; Lakshmi Vasudevan; Bronwen Martin; Stuart Maudsley
Journal:  Int J Mol Sci       Date:  2022-04-15       Impact factor: 6.208

5.  Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.

Authors:  A Aragón-Herrera; S Feijóo-Bandín; D Rodríguez-Penas; E Roselló-Lletí; M Portolés; M Rivera; M Bigazzi; D Bani; O Gualillo; J R González-Juanatey; F Lago
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

Review 6.  Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.

Authors:  Jigna Rajesh Kumar; Ramamoorthy Rajkumar; Tharindunee Jayakody; Subhi Marwari; Jia Mei Hong; Sherie Ma; Andrew L Gundlach; Mitchell K P Lai; Gavin S Dawe
Journal:  Br J Pharmacol       Date:  2016-09-06       Impact factor: 8.739

7.  Comparative Distribution of Relaxin-3 Inputs and Calcium-Binding Protein-Positive Neurons in Rat Amygdala.

Authors:  Fabio N Santos; Celia W Pereira; Ana M Sánchez-Pérez; Marcos Otero-García; Sherie Ma; Andrew L Gundlach; Francisco E Olucha-Bordonau
Journal:  Front Neuroanat       Date:  2016-04-07       Impact factor: 3.856

Review 8.  Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago
Journal:  Front Physiol       Date:  2017-08-18       Impact factor: 4.566

9.  RLN3/RXFP3 Signaling in the PVN Inhibits Magnocellular Neurons via M-like Current Activation and Contributes to Binge Eating Behavior.

Authors:  Alan Kania; Agata Szlaga; Patryk Sambak; Anna Gugula; Ewa Blasiak; Maria Vittoria Micioni Di Bonaventura; Mohammad Akhter Hossain; Carlo Cifani; Grzegorz Hess; Andrew L Gundlach; Anna Blasiak
Journal:  J Neurosci       Date:  2020-06-12       Impact factor: 6.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.